Literature DB >> 3905298

Fibronectin in formation and degradation of the pericellular matrix.

A Vaheri, E M Salonen, T Vartio.   

Abstract

Fibronectin is a large multifunctional glycoprotein present both in soluble form in plasma and other body fluids and in an insoluble form in interstitial connective tissues and in association with most basement membranes. The protein seems to provide a link between circulating body fluids, cell surfaces and the extracellular matrix. At sites of injury, fibronectin, covalently cross-linked to the fibrin clot, may provide a growth substratum for the invading cells and appears through its multiple interactions with other matrix components and cell surfaces to be involved in the organization of the matrix that will replace the clot. Fibronectin deposition may serve as a useful early marker for connective tissue formation in pathological processes and its fragmentation may serve as an indicator of pathological conditions involving proteolytic events.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905298     DOI: 10.1002/9780470720950.ch8

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  10 in total

1.  Identification of an alternatively spliced site in human plasma fibronectin that mediates cell type-specific adhesion.

Authors:  M J Humphries; S K Akiyama; A Komoriya; K Olden; K M Yamada
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

2.  Histochemical study of alkali-burned rabbit anterior eye segment in which severe lesions were prevented by aprotinin treatment.

Authors:  J Cejková; Z Lojda; E M Salonen; A Vaheri
Journal:  Histochemistry       Date:  1989

3.  Kinetics of transforming growth factor-beta1 and extracellular matrix in renal tubulointerstitial lesions of mercuric chloride-treated Brown Norway rats.

Authors:  K Suzuki; K Uetsuka; H Nakayama; K Doi
Journal:  Int J Exp Pathol       Date:  1999-06       Impact factor: 1.925

4.  Sequential changes of extracellular matrix and proliferation of Ito cells with enhanced expression of desmin and actin in focal hepatic injury.

Authors:  K Ogawa; J Suzuki; H Mukai; M Mori
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

5.  Activated human peripheral blood neutrophils produce epithelial injury and fibronectin breakdown in vitro.

Authors:  D M Brown; G M Brown; W Macnee; K Donaldson
Journal:  Inflammation       Date:  1992-02       Impact factor: 4.092

6.  Histochemical changes in the rabbit cornea and plasmin activity in the tear fluid during contact lens wear. Favourable influence of protease inhibitors (aprotinin, PC5, elastatinal).

Authors:  J Cejková; Z Lojda; J Vacík; G A Digenis; S Dropcova
Journal:  Histochemistry       Date:  1992

7.  Cellular fibronectin and tenascin in experimental perforating scleral wounds with incarceration of the vitreous.

Authors:  K Tervo; T Latvala; V P Suomalainen; T Tervo; I Immonen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-03       Impact factor: 3.117

8.  Contact lens wear is associated with the appearance of plasmin in the tear fluid--preliminary results.

Authors:  T Tervo; G B van Setten; R Andersson; E M Salonen; A Vaheri; I Immonen; A Tarkkanen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

9.  Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it.

Authors:  E M Salonen; M Jauhiainen; L Zardi; A Vaheri; C Ehnholm
Journal:  EMBO J       Date:  1989-12-20       Impact factor: 11.598

10.  Monoclonal Antibody to Marinobufagenin Downregulates TGFβ Profibrotic Signaling in Left Ventricle and Kidney and Reduces Tissue Remodeling in Salt-Sensitive Hypertension.

Authors:  Yongqing Zhang; Wen Wei; Victoria Shilova; Natalia N Petrashevskaya; Valentina I Zernetkina; Yulia N Grigorova; Courtney A Marshall; Rachel C Fenner; Elin Lehrmann; William H Wood; Kevin G Becker; Edward G Lakatta; Alexei Y Bagrov; Olga V Fedorova
Journal:  J Am Heart Assoc       Date:  2019-10-02       Impact factor: 6.106

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.